Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells $14,316.12 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Robert Allen III sold 17,043 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total transaction of $14,316.12. Following the completion of the transaction, the insider owned 178,765 shares of the company’s stock, valued at $150,162.60. This represents a 8.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Invivyd Stock Down 0.9%

Shares of NASDAQ IVVD opened at $0.95 on Friday. Invivyd, Inc. has a 52 week low of $0.48 and a 52 week high of $3.07. The firm has a 50-day moving average price of $0.78 and a 200 day moving average price of $1.22. The stock has a market capitalization of $280.26 million, a price-to-earnings ratio of -2.88 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The company had revenue of $14.29 million for the quarter, compared to analysts’ expectations of $14.40 million. Equities research analysts expect that Invivyd, Inc. will post -0.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Invivyd

Several hedge funds have recently added to or reduced their stakes in the business. Chicago Partners Investment Group LLC acquired a new position in Invivyd during the first quarter worth about $25,000. Courier Capital LLC purchased a new stake in shares of Invivyd in the fourth quarter valued at about $25,000. Bronte Capital Management Pty Ltd. purchased a new stake in shares of Invivyd in the fourth quarter valued at about $27,000. DRW Securities LLC acquired a new stake in shares of Invivyd in the fourth quarter valued at approximately $27,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Invivyd in the fourth quarter valued at approximately $30,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating on shares of Invivyd in a research note on Tuesday. Wall Street Zen downgraded Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a research report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.